| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, North America Commercial | EVP Global Marketing&Portfolio
1 company
Dethlefs Sven is an EVP, North America Commercial at TEVA. Recent filings cover 1 purchase and 20 sales. Those positions are worth an estimated $1.6M at current prices.
Our model assigns Dethlefs Sven a below-average insider score of 39/100, based on 7 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -29.5%.
Dethlefs Sven's largest disclosed position is in TEVA as EVP, North America Commercial, worth about $1.6M. The recent filings there lean toward selling, a net 208,060 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 7, 2023 | TEVA Teva Pharmaceutical Industries Ltd | EVP, North America Commercial | Sell | 77,421 | $9.55 | $739,653.01 | -31.9% | -23.6% | +43.3% | |
| Feb 28, 2023 | TEVA Teva Pharmaceutical Industries Ltd | EVP, North America Commercial | Sale+OE | 59,655 | $9.89 | $589,785.12 | -26.5% | -27.2% | +32.1% | |
| Mar 7, 2022 | TEVA Teva Pharmaceutical Industries Ltd | EVP, North America Commercial | Sale+OE | 10,897 | $7.41 | $80,727.01 | -6.2% | +23.6% | +28.8% | |
| Feb 28, 2022 | TEVA Teva Pharmaceutical Industries Ltd | EVP, North America Commercial | Sale+OE | 4,862 | $8.14 | $39,587.38 | -4.7% | +11.9% | +21.9% | |
| Feb 9, 2022 | TEVA Teva Pharmaceutical Industries Ltd | EVP, North America Commercial | Sale+OE | 4,138 | $9.06 | $37,491.11 | -4.5% | -16.7% | +9.2% | |
| Mar 4, 2021 | TEVA Teva Pharmaceutical Industries Ltd | EVP Global Marketing&Portfolio | Sale+OE | 6,012 | $10.57 | $63,523.39 | -7.2% | - | - | |
| Mar 3, 2021 | TEVA Teva Pharmaceutical Industries Ltd | EVP Global Marketing&Portfolio | Sale+OE | 606 | $10.86 | $6,582.74 | -0.9% | - | - | |
| Mar 1, 2021 | TEVA Teva Pharmaceutical Industries Ltd | EVP Global Marketing&Portfolio | Sale+OE | 7,486 | $10.83 | $81,079.37 | -9.8% | - | - | |
| Feb 9, 2021 | TEVA Teva Pharmaceutical Industries Ltd | EVP Global Marketing&Portfolio | Sale+OE | 29,657 | $12.69 | $376,480.79 | -33.3% | - | - | |
| Feb 10, 2020 | TEVA Teva Pharmaceutical Industries Ltd | EVP Global Marketing&Portfolio | Sale+OE | 5,669 | $12.27 | $69,558.63 | -23.9% | - | - |